| Biomarker ID | 1317 |
| PMID | 24448834 |
| Year | 2014 |
| Biomarker | DAB2 [SNP: rs268091: GC/CC versus GG] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Increased risk of Progression |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.36 (95% CI: 0.16–0.80) |
| Effect on Pathways | Pathways include: Gap junction degradation, Gap junction trafficking and regulation, Membrane trafficking, TGF-beta signaling pathway, Endocytosis |
| Experiment | PCa Specific Mortality Vs No Mortality During ADT |
| Type of Biomarker | Prognostic |
| Cohort | 321 patients with localized prostate cancer who underwent radical prostatectomy (RP) as initial treatment and 605 patients with advanced prostate cancer on androgen-deprivation therapy (ADT) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.012 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |